EMO can reduce hepatic lipogenesis and increase insulin sensitivity to combat insulin resistance (IR) by upregulating phosphatidylinositol 3-kinase (PI3K), AKT2, and AMPKα. This evidence concerns the gene INS and Insulin resistance.